- Home
- TBI vs TIL Comparison
TBI vs TIL Comparison
Compare TBI & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBI
- TIL
- Stock Information
- Founded
- TBI 1985
- TIL 2018
- Country
- TBI United States
- TIL United States
- Employees
- TBI N/A
- TIL N/A
- Industry
- TBI Professional Services
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- TBI Consumer Discretionary
- TIL Health Care
- Exchange
- TBI Nasdaq
- TIL Nasdaq
- Market Cap
- TBI 169.0M
- TIL 171.7M
- IPO Year
- TBI 1996
- TIL 2021
- Fundamental
- Price
- TBI $5.80
- TIL $32.65
- Analyst Decision
- TBI Buy
- TIL Buy
- Analyst Count
- TBI 1
- TIL 5
- Target Price
- TBI $10.00
- TIL $119.00
- AVG Volume (30 Days)
- TBI 525.7K
- TIL 316.4K
- Earning Date
- TBI 05-05-2025
- TIL 05-13-2025
- Dividend Yield
- TBI N/A
- TIL N/A
- EPS Growth
- TBI N/A
- TIL N/A
- EPS
- TBI N/A
- TIL N/A
- Revenue
- TBI $1,534,794,000.00
- TIL N/A
- Revenue This Year
- TBI $0.80
- TIL N/A
- Revenue Next Year
- TBI $6.90
- TIL N/A
- P/E Ratio
- TBI N/A
- TIL N/A
- Revenue Growth
- TBI N/A
- TIL N/A
- 52 Week Low
- TBI $3.45
- TIL $9.62
- 52 Week High
- TBI $12.29
- TIL $92.00
- Technical
- Relative Strength Index (RSI)
- TBI 61.64
- TIL 65.08
- Support Level
- TBI $5.82
- TIL $12.60
- Resistance Level
- TBI $6.28
- TIL $35.28
- Average True Range (ATR)
- TBI 0.36
- TIL 3.84
- MACD
- TBI 0.07
- TIL 1.60
- Stochastic Oscillator
- TBI 70.33
- TIL 63.27
About TBI TrueBlue Inc.
TrueBlue Inc is a provider of staffing and workforce management solutions. Its reportable segments include PeopleReady offers industrial staffing services. PeopleManagement offers contingent and productivity-based on-site industrial staffing services and PeopleScout offers recruitment process outsourcing, talent advisory services, and managed service provider services. It generates maximum revenue from the PeopleReady segment.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize FRα, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.